Vadivarhe Speci.

When is the next results date for Vadivarhe Speci.?

No Upcoming Board Meetings

Has Vadivarhe Speci. declared dividend?

No Dividend History Available

Who are the peers of the Vadivarhe Speci.?

Vadivarhe Speci.'s peers include Hi-Green Carbon, Sanginita Chemi., Shri Ahimsa, Indian Emuls, Arvee Laborat., Hindcon Chemical, Indian Phosphate, Vital Chemtech, Jocil, and Paragon Fine. All peers, including Vadivarhe Speci., have a 1-year return of 0.00%.

Peers: The peers of Vadivarhe Speci. are Hi-Green Carbon, Sanginita Chemi., Shri Ahimsa, Indian Emuls, Arvee Laborat., Hindcon Chemical, Indian Phosphate, Vital Chemtech, Jocil, Paragon Fine.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shri Ahimsa, Indian Emuls, and Indian Phosphate, while Good management risk is found at Hi-Green Carbon, Arvee Laborat., and Paragon Fine. Average management risk is present at Hindcon Chemical, Vital Chemtech, and Jocil, while Below Average management risk is noted at Sanginita Chemi. and Vadivarhe Speci. Growth is Excellent at Indian Emuls, Good at Shri Ahimsa, Indian Phosphate, and Paragon Fine, Average at Hi-Green Carbon and Arvee Laborat., and Below Average at Sanginita Chemi., Hindcon Chemical, Vital Chemtech, Jocil, and Vadivarhe Speci. Capital Structure is Excellent at Shri Ahimsa, Hindcon Chemical, and Jocil, Good at Hi-Green Carbon, Arvee Laborat., and Indian Phosphate, and Below Average at Sanginita Chemi., Indian Emuls, Vital Chemtech, and Vadivarhe Speci.<BR><BR>Return Snapshot: All peers, including Vadivarhe Speci., have a 1-year return of 0.00%, indicating no variation among them. There are no peers with a negative six-month return.

Is Vadivarhe Speci. overvalued or undervalued?

As of April 25, 2023, Vadivarhe Speciality is classified as risky and overvalued, with poor financial metrics including a PE ratio of -4.44 and a year-to-date return of -39.39%, significantly underperforming compared to its peers and the Sensex.

As of 25 April 2023, the valuation grade for Vadivarhe Speciality has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued based on its current metrics, which include a PE ratio of -4.44, an EV to EBITDA of -12.38, and a ROE of -119.89%. These ratios suggest that the company is struggling to generate positive returns and is facing considerable financial challenges.<BR><BR>In comparison to its peers, Vadivarhe Speciality's valuation stands out negatively. For instance, Solar Industries India Ltd. is classified as very expensive with a PE ratio of 123.77, while Godrej Industries Ltd. is considered attractive with a PE ratio of 46.63. The stark contrast in valuations highlights the difficulties faced by Vadivarhe Speciality. Additionally, the company's year-to-date return of -39.39% significantly underperforms the Sensex's gain of 6.20%, further reinforcing the notion that it is currently overvalued in the market.

What is the technical trend for Vadivarhe Speci.?

As of May 29, 2025, Vadivarhe Speci. shows a bearish trend with moderate strength, supported by bearish daily moving averages and KST, despite conflicting signals from the MACD.

As of 29 May 2025, the technical trend for Vadivarhe Speci. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD is mildly bullish, but the monthly MACD indicates a bearish trend, which is a conflicting signal. The daily moving averages are bearish, reinforcing the negative outlook. Additionally, both the weekly and monthly KST are bearish, and Bollinger Bands are mildly bearish across both time frames. There are no significant signals from the RSI or Dow Theory, which show no trend. Overall, the bearish indicators dominate, suggesting caution for investors.

Who are in the management team of Vadivarhe Speci.?

As of March 2022, the management team of Vadivarhe Speci. includes Sunil H Pophale (Director), Meena S Pophale (Whole-time Director), Pramod W Gajare (Whole-time Director), and independent directors Ravindra K Paranjpe, Prasanna P Rege, and Uttara A Kher.

As of March 2022, the management team of Vadivarhe Speci. includes the following individuals:<BR><BR>1. Sunil H Pophale - Director<BR>2. Meena S Pophale - Whole-time Director<BR>3. Ravindra K Paranjpe - Independent Director<BR>4. Prasanna P Rege - Independent Director<BR>5. Uttara A Kher - Independent Director<BR>6. Pramod W Gajare - Whole-time Director<BR><BR>This team comprises both executive and independent directors, contributing to the governance and management of the company.

What does Vadivarhe Speci. do?

Vadivarhe Speciality Chemicals Ltd is a Micro Cap company in the Chemicals & Petrochemicals industry, incorporated in 2009, with recent net sales of 57 Cr and a net profit of -29 Cr as of December 2021. The company has a market cap of INR 41 Cr and significant debt, reflected in a debt-equity ratio of 3.95.

Overview:<BR>Vadivarhe Speciality Chemicals Ltd operates in the Chemicals & Petrochemicals industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated on February 23, 2009. Prior to its incorporation, it was promoted by Mr. Sunil Haripant Pophale under the name Fem Care Pharma Ltd, which was later taken over by Dabur India Limited in 2009. The latest quarterly results reported net sales and profit for December 2021.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 57 Cr (Quarterly Results - Dec 2021) <BR>Most recent Net Profit: -29 Cr (Quarterly Results - Dec 2021) <BR>Market-cap value: INR 41 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 3.95 <BR>Return on Equity: -119.89% <BR>Price to Book: 6.30<BR><BR>Contact Details:<BR>Address: Gat No 204 Vadivarhe Igatpu, Igatpuri Maharashtra: 422403 <BR>Tel: 91-2553-282200 <BR>Email: cs@vscl.co.in / inquiry@vscl.in <BR>Website: http://www.vscl.net.in

Who are the top shareholders of the Vadivarhe Speci.?

The top shareholder of Vadivarhe Speci. is Meena Sunil Pophale, holding 47.24%, with no pledged promoter holdings. The highest public shareholder is Sanjaykumar Harikishan at 1.67%, while individual investors own 26.7% of the shares.

The top shareholders of Vadivarhe Speci. are primarily the promoters, with Meena Sunil Pophale holding the largest share at 47.24%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sanjaykumar Harikishan, who owns 1.67%. Additionally, individual investors collectively hold 26.7% of the company's shares.

How big is Vadivarhe Speci.?

As of 23rd July, Vadivarhe Speciality Chemicals Ltd has a market capitalization of 38.00 Cr, with Net Sales of 23.77 Cr and a Net Profit loss of 7.52 Cr over the latest four quarters. The balance sheet for March 2024 shows Shareholder's Funds of 6.49 Cr and Total Assets of 41.61 Cr.

As of 23rd July, Vadivarhe Speciality Chemicals Ltd has a market capitalization of 38.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 23.77 Cr. However, it experienced a loss of 7.52 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 6.49 Cr and Total Assets amounting to 41.61 Cr.

How has been the historical performance of Vadivarhe Speci.?

Vadivarhe Speci. has experienced declining financial performance, with net sales dropping from 43.68 Cr in March 2023 to 37.91 Cr in March 2025, and significant losses in operating profit and profit after tax. The company's total liabilities increased, indicating financial pressure and ongoing challenges in cash flow generation.

Answer:<BR>The historical performance of Vadivarhe Speci. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Vadivarhe Speci. reported net sales of 37.91 Cr in March 2025, a decline from 40.08 Cr in March 2024 and 43.68 Cr in March 2023, which were significantly higher than the 21.45 Cr recorded in March 2022. The total operating income followed a similar trend, decreasing from 40.08 Cr in March 2024 to 37.91 Cr in March 2025. The company's total expenditure increased to 44.32 Cr in March 2025, up from 36.03 Cr in March 2024, leading to an operating profit (PBDIT) of -6.14 Cr in March 2025, down from 4.54 Cr in the previous year. Profit before tax also fell to -9.27 Cr in March 2025, compared to 1.51 Cr in March 2024. Consequently, the profit after tax was -9.27 Cr in March 2025, a significant drop from 0.06 Cr in March 2024. The company's total liabilities increased to 42.73 Cr in March 2025, while total assets were reported at 42.73 Cr, indicating a balance sheet under pressure. Cash flow from operating activities was -7.00 Cr in March 2025, reflecting ongoing challenges in generating positive cash flow. Overall, the financial performance of Vadivarhe Speci. has shown a downward trajectory in recent years, particularly in profitability and cash flow metrics.

Should I buy, sell or hold Vadivarhe Speci.?

Why is Vadivarhe Speciality Chemicals Ltd falling/rising?

As of 04-Feb, Vadivarhe Speciality Chemicals Ltd's stock price is stable at 21.35, with recent short-term gains of +4.91% and +20.96% over the past week and month, respectively. However, the stock faces significant long-term challenges, including a -45.95% decline over the past year and concerns about financial health due to a lack of recent results and high debt levels.

As of 04-Feb, Vadivarhe Speciality Chemicals Ltd's stock price is currently stable at 21.35, showing no change (0.00%). However, the stock has exhibited a positive trend over the past week and month, with returns of +4.91% and +20.96%, respectively, while the benchmark Sensex has only increased by +1.71% and decreased by -2.10% in the same periods. This indicates that the stock is outperforming the market recently.<BR><BR>Despite this short-term positive performance, the stock has significant long-term challenges. Over the past year, it has experienced a substantial decline of -45.95%, and its profits have fallen dramatically by -299%. The company has not declared results in the last six months, raising concerns about its financial health and ability to service its debt, as indicated by a high Debt to EBITDA ratio of -1.00 times. Additionally, the average Return on Equity is low at 0.89%, reflecting poor profitability.<BR><BR>Investor participation has increased, with a 25% rise in delivery volume on February 2 compared to the 5-day average, suggesting some interest in the stock. However, the overall sentiment remains cautious due to the company's weak long-term fundamentals and the absence of recent financial results. Thus, while there may be short-term gains, the long-term outlook appears risky, contributing to the stock's overall decline in value over the past year.

Which are the latest news on Vadivarhe Speci.?